



Review

Targeting virulence mechanisms for the prevention and therapy of arenaviral hemorrhagic fever



Lisa McLay^a, Aftab Ansari^a, Yuying Liang^b, Hinh Ly^{a,b,*}

^a Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, United States

^b Department of Veterinary and Biomedical Sciences, University of Minnesota, Twin Cities, MN 55108, United States

ARTICLE INFO

Article history:

Received 27 October 2012

Revised 28 November 2012

Accepted 7 December 2012

Available online 20 December 2012

Keywords:

Arenavirus

Lassa virus

Viral hemorrhagic fever

Virulence mechanisms

Antiviral therapy

ABSTRACT

A number of arenaviruses are pathogenic for humans, but they differ significantly in virulence. Lassa virus, found in West Africa, causes severe hemorrhagic fever (HF), while the other principal Old World arenavirus, lymphocytic choriomeningitis virus, causes mild illness in persons with normal immune function, and poses a threat only to immunocompromised individuals. The New World agents, including Junin, Machupo and Sabia virus, are highly pathogenic for humans. Arenaviral HF is characterized by high viremia and general immune suppression, the mechanism of which is unknown. Studies using viral reverse genetics, cell-based assays, animal models and human genome-wide association analysis have revealed potential mechanisms by which arenaviruses cause severe disease in humans. Each of the four viral gene products (GPC, L polymerase, NP, and Z matrix protein) and several host-cell factors (e.g., α -dystroglycan) are responsible for mediating viral entry, genome replication, and the inhibition of apoptosis, translation and interferon-beta (IFN β) production. This review summarizes current knowledge of the role of each viral protein and host factor in the pathogenesis of arenaviral HF. Insights from recent studies are being exploited for the development of novel therapies.

© 2012 Elsevier B.V. All rights reserved.

Contents

1. Introduction: arenaviral diseases of humans	82
1.1. Old World arenaviruses	82
1.2. New World arenaviruses.	83
2. Arenavirus genome structure and replication cycle.	83
2.1. Genome structure	83
2.2. Receptor binding	83
2.3. Membrane fusion and entry.	84
2.4. Genome replication and transcription	85
2.5. Post-translational protein processing.	85
2.6. Role of the Z protein in arenaviral replication.	85
3. The role of individual arenaviral proteins in HF pathogenesis	86
3.1. Role of the glycoprotein (GP) in pathogenesis.	86
3.2. Role of the nucleoprotein (NP) in pathogenesis	86
3.3. Role of the polymerase (L) protein in pathogenesis	87
3.4. Role of the Z protein in pathogenesis	87
4. Antiviral compounds targeting different steps of the arenaviral life cycle.	87
4.1. Compounds targeting viral entry	87
4.2. Compounds targeting the viral RNA polymerase.	87
4.3. Compounds targeting post-translational protein modification.	88
4.4. Compounds targeting the Z protein.	88
5. Host immune suppression and inflammatory responses.	88

* Corresponding author. Address: Department of Veterinary and Biomedical Sciences, University of Minnesota, 1988 Fitch Ave., Ste 295, Saint Paul, MN 55108, United States. Tel.: +1 612 625 3358; fax: +1 612 625 0204.

E-mail address: hly@umn.edu (H. Ly).

6. Conclusion	89
Acknowledgements	89
References	89

1. Introduction: arenaviral diseases of humans

The *Arenaviridae* family consists of a large group of single-stranded ambisense RNA viruses that are separated phylogenetically, serologically, and geographically into Old World (OW) and New World (NW) viruses. Some viruses from both groups cause significant morbidity and mortality in humans. Lassa virus, found in West Africa, causes severe hemorrhagic fever (HF), while the other principal OW arenavirus, lymphocytic choriomeningitis virus (LCMV), produces only mild illness in immunocompetent humans. In contrast, Junin virus (JUNV) and the other NW arenaviruses found in South America, cause severe hemorrhagic fever (HF). There are currently limited prevention and treatment measures against these pathogenic arenaviruses. The only available vaccine (Candid #1) has been developed and used extensively to prevent Argentine hemorrhagic fever (AHF) caused by JUNV (Maiztegui et al., 1998). Ribavirin, the only licensed antiviral for the treatment of arenaviral hemorrhagic fevers, has had mixed success and significant toxicity in treating arenaviral HF (Günther and Lenz, 2004).

A major question is why some arenaviruses cause severe disease in humans, while others do not. Many factors have been proposed to explain the differential degrees of pathogenicity, such as host genetic polymorphism, routes and doses of infection, and viral virulence factors. It has been postulated that virulent arenaviruses are able to replicate to high levels and can effectively suppress host immunity. Recent studies using viral reverse genetics, cell-based assays, animal models, and human genome wide association analyses have revealed potential mechanisms that arenaviruses utilize to cause virulent infections in the hosts. Understanding viral virulence mechanisms is expected to facilitate the development of appropriate preventive and therapeutic strategies against these deadly viral hemorrhagic fevers. This paper summarizes current progress in understanding the roles of viral factors in mediating efficient viral entry, enhanced viral RNA synthesis, inhibition of cellular apoptosis, translation and host innate immunity, all of which contribute to the virulence of pathogenic arenaviruses for humans.

1.1. Old World arenaviruses

Lassa virus (LASV) causes Lassa fever, resulting in approximately 2 million infections and 5–10,000 deaths annually in endemic area of West Africa (McCormick, 1999). LASV infection results in heterogeneity in disease manifestation that ranges from non-symptomatic to multi-organ failure and death. Patients infected with LASV are often misdiagnosed because of the wide range of symptoms they may exhibit. These symptoms include fever, malaise, petechial hemorrhage, edema, nausea, vomiting and diarrhea (Moraz and Kunz, 2010). Up to one third of patients experience sensorineural deafness which remains even after recovery from the illness (Cummins et al., 1990). Fatal cases may display respiratory distress, shock, encephalopathy, seizures, shock, coma, and mucosal bleeding (Moraz and Kunz, 2010).

Lujo virus (LUJV), the only other known hemorrhagic fever-causing OW arenavirus, was identified during an outbreak of the disease in Lusaka (Zambia) and Johannesburg (Republic of South Africa) in 2008 (Briese et al., 2009). Symptoms noted for patients infected with Lujo virus include fever, edema, mild bleeding, elevated liver transaminases, and thrombocytopenia (Paweska et al., 2009).

Lymphocytic choriomeningitis virus (LCMV), which is found worldwide, has also been identified as pathogenic for immunocompromised individuals (Al-Zein et al., 2008; Fischer et al., 2006; MacNeil et al., 2012; Centers for Disease Control and Prevention, 2008). The data at hand suggests that approximately 5% of the human population show evidence of exposure to LCMV, however, most acquired infections are asymptomatic or mild (Table 1) (Peters, 2006; Rousseau et al., 1997). Because the natural host of LCMV, *Mus musculus*, has a worldwide distribution, this virus can likewise be found in most regions. While acquired LCMV infection does not pose a serious threat to the general population, congenital infection with LCMV can be quite serious. This infection can result in spontaneous abortion and fetal death, or leave the infant with brain dysfunction. The incidence of congenital LCMV infection is unknown, as only serious cases are investigated for the cause of infection and reported (Bonthius, 2012). While 35% of reported

Table 1
Human disease caused by Old World arenavirus infection.

	Syndrome produced in humans	Incidence of disease
LCMV (Worldwide)	<i>Acquired</i> : most cases are mild or asymptomatic. Symptoms include fever, cough, malaise, myalgia, headache, photophobia, nausea, vomiting, adenopathy, sore throat, thrombocytopenia, and leukopenia. Severe cases may develop meningitis or meningoencephalitis [1,2] <i>Congenital</i> : spontaneous abortion and fetal death, vision impairment (via chorioretinitis), brain dysfunction (macrocephaly due to inflammation or microcephaly due to lack of growth and immune mediation destruction of brain tissue) [3] <i>Transplant associated</i> : severe disease – encephalopathy, coagulopathy, abdominal pain, thrombocytopenia, fever, leukocytosis, graft dysfunction	<i>Acquired</i> : >5% of humans show evidence of LCMV exposure <1% mortality [1] <i>Congenital</i> : unknown, only severe cases are investigated and reported <i>Transplant</i> : 14 cases, 11 fatal [4–6]
Lassa virus (West Africa)	Fever, weakness, malaise, cough, severe headache, sore throat, nausea, vomiting, diarrhea, sensorineural deafness. Facial edema, pleural effusion, thrombocytopenia, and leukopenia are seen in more serious cases. Fatal cases may exhibit pulmonary edema, respiratory distress, shock, encephalopathy, seizures, coma, and bleeding from mucosal surfaces [7]	~2 million infections annually and 5000–10,000 deaths [8]
Lujo virus (South Africa)	Diarrhea, vomiting, fever, chest pain, sore throat, rash, myalgia, facial swelling, respiratory distress, cerebral edema, thrombocytopenia, elevated liver transaminases, fever, mild bleeding in 3 patients, leukopenia [9]	Cases, 4 fatal

[1] Peters (2006); [2] Rousseau et al. (1997); [3] Bonthius (2012); [4] Fischer et al. (2006); [5] MacNeil et al. (2012); [6] Centers for Disease Control and Prevention (2008); [7] Moraz and Kunz (2010); [8] McCormick (1999); [9] Paweska et al. (2009).

Table 2
Human disease caused by New World arenavirus infection.

	Syndrome produced in humans	Incidence of disease
Junín virus (Argentina)	Fever, myalgia, mild hypotension, conjunctivitis, petechiae in the axilla, soft palate, or gingival margin. Neurological symptoms such as irritability, lethargy, and hyporeflexia. Severe cases may exhibit hemorrhagic manifestations, leukopenia, thrombocytopenia, shock, and seizures [1]	<i>Before vaccine:</i> 300–1000 cases/year. <i>After vaccine:</i> 30–50 cases/year 15–30% mortality [1–3]
Machupo virus (Bolivia)	Fever, gingival hemorrhage, petechiae, nausea, gastrointestinal hemorrhage, thrombocytopenia, leukopenia, hematuria, tremor, asthenia, anorexia, and respiratory distress [4]	1962–1964: 1000 cases 1990s: 19 cases 2007–2008: >200 cases ~ 20% mortality [4,5]
Sabiá virus (Brazil)	Fever, headache, myalgia, nausea, vomiting, weakness, leukopenia, elevated liver transaminases, hematemesis, mucosal bleeding, conjunctival petechiae, tremors, coma, shock, pulmonary edema, hepatic hemorrhage and necrosis, gastrointestinal hemorrhage [6]	1 naturally occurring case, fatal
Guanarito virus (Venezuela)	Fever, malaise, headache, arthralgia, sore throat, vomiting, abdominal pain, diarrhea, convulsions, leukopenia, thrombocytopenia, various hemorrhagic manifestations [7]	618 cases, 23% fatal [8]
Chapare virus (Bolivia)	Fever, arthralgia, myalgia, vomiting, hemorrhage [9]	1 confirmed case, fatal

[1] Harrison et al. (1999); [2] Enria et al. (2008); [3] Ambrosio et al. (2011); [4] Aguilar et al. (2009); [5] Charrel and Lamballerie (2003); [6] Lisieux et al. (1994); [7] Manzione et al. (1998); [8] Fulhorst et al. (2008); [9] Delgado et al. (2008).

We examine the role of each gene product, plus host factors, in arenavirus virulence.

cases of congenital LCMV infection are fatal (Wright et al., 1997), we do not know the incidence of mild or asymptomatic congenital LCMV infections, as infants are not tested for infection. In recent years, LCMV has proven to be an important pathogen for transplant recipients. Fourteen cases of LCMV infection in transplant recipients have been identified, eleven of which have proven fatal (Fischer et al., 2006; MacNeil et al., 2012; Centers for Disease Control and Prevention, 2008).

1.2. New World arenaviruses

Several NW American arenaviruses, such as JUNV, Machupo (MACV), Guanarito (GTOV), Chapare (CHPV) and Sabia (SABV), can cause HF with high mortality rates. The disease courses for NW arenavirus infections also show some differences (Table 2). While only one human infection has been noted each for SABV and CHPV (Delgado et al., 2008; Lisieux et al., 1994), JUNV, MACV and GTOV have caused many cases of human disease (Aguilar et al., 2009; Ambrosio et al., 2011; Charrel and Lamballerie, 2003; Enria et al., 2008; Fulhorst et al., 2008; Harrison et al., 1999; Manzione et al., 1998). Many of the arenaviral hemorrhagic fevers (both NW and OW) display shared symptoms, with some variation in manifestation of disease caused by these related pathogens. Frequently, individuals with severe arenaviral hemorrhagic fever develop fever, petechial hemorrhage, edema, respiratory distress, shock, thrombocytopenia, leukopenia, and mucosal bleeding. While hepatitis is common in severe cases of Lassa fever, hepatitis is unusual or mild in South American hemorrhagic fevers. Neurologic symptoms, hemorrhaging, leukopenia, and thrombocytopenia are much more common in JUNV, GTOV, or MACV infection than LASV infection (Pfau, 1996).

2. Arenavirus genome structure and replication cycle

2.1. Genome structure

Arenaviruses are enveloped, ambisense RNA viruses with a single-stranded genome composed of two segments (Fig. 1). The genomic L (large) segment encodes the Z matrix protein and the L polymerase protein, while the S (small) segment encodes the glycoprotein (GPC) and nucleoprotein (NP). The genes encoded within each segment are separated by an intergenic region (IGR) with secondary structure that is thought to be involved in viral mRNA transcriptional termination (Pinschewer et al., 2005). The genomic




Fig. 1. Arenavirus genome structure. Arenaviruses are enveloped, ambisense RNA viruses with a single stranded genome composed of two segments: the genomic L (large) segment encodes the Z matrix protein and the L polymerase protein, and the S (small) segment encodes the glycoprotein (GPC) and nucleoprotein (NP). The genes encoded within each segment are separated by noncoding regions: the intergenic (IGR) region with strong secondary structures and the conserved 5' and 3' untranslated regions (UTR) at the termini of the genomic segments.

segments contain conserved 5' and 3' untranslated regions (UTR) that are complementary to each other and form a panhandle structure at the end of the viral genome (Perez and de la Torre, 2003).

2.2. Receptor binding

The life cycle of arenaviruses (Fig. 2) begins with cellular entry that is mediated by different cellular receptors. OW arenaviruses, along with NW clade C viruses Oliveros and Latino, use cellular α -dystroglycan (α DG) as their receptor in order to gain entry into the cell (Cao et al., 1998; Kunz et al., 2001; Spiropoulou et al., 2002). Dystroglycan is post-translationally cleaved to the subunit α DG, which contains the binding site for arenaviruses, and β DG, which spans the cell membrane and binds dystrophin on the interior of the cell, thus linking the molecule to the cytoskeletal network. This cell surface molecule anchors the cell by binding to laminin, a component of the extracellular matrix (ECM). α DG is expressed on many cell types, which accounts for the pantropic nature of OW arenavirus infection. In mice, this receptor has been shown to be highly expressed on dendritic cells, which are early targets in arenavirus infections, allowing the virus to suppress the immune response (Sevilla et al., 2000) (see below for more details). On the contrary, very little α DG is expressed on CD4, CD8, and B cells, which arenaviruses fail to infect (Sevilla et al., 2000). When the virus binds to α DG, it displaces laminin. This can result in destabilization of the membrane and potentially a loss of cellu-




Fig. 2. Arenavirus life cycle and compounds that can block different steps of the virus life cycle. (1) Cellular entry is mediated by different cellular receptors (α DG for OW and NW clade C arenaviruses, Tfr1 for NW Clade B). (2) Virus uptake into cells is mediated by endocytosis (OW arenaviruses: clathrin independent, NW: clathrin dependent). (3) Virus fusion occurs with the late endosome (OW arenaviruses bypass the early endosome). (4) Viral RNP is released into the cytoplasm via a pH dependent membrane fusion mechanism (mediated by GP2 of the viral glycoprotein). (5) Viral genome replication, transcription, and protein expression occur in the cytoplasm (cap snatching is utilized for generation of viral mRNA). (6) Viral GPC precursor is cleaved into SSP, GP1 and GP2 proteins (SSP cleaved in ER by signal peptidase, GP1 and GP2 cleaved in either ER or Golgi by S1P/SKI-1). (7) Virion assembly and budding occur at the plasma membrane. (8) Progeny virion particle is released. As the mechanism of the arenaviral life cycle is better understood, several compounds have been tested experimentally (e.g., T-705, amphipathic DNA polymers, ST-193, ST-294, PPMOs, 3f, siRNA, PF429241, and myristic acid analogs) and in the field (e.g., ribavirin) to block different steps of the virus life cycle.

lar signaling, which can contribute to pathogenesis (Rojek et al., 2012).

In order for α DG to function properly as an ECM receptor, it must first be post-translationally modified. This receptor is composed of two globular domains, located at each terminus, separated by a mucin-like domain. The cellular like-acetylglucosaminyltransferase (LARGE) recognizes the α -mannosylated N terminal end of the mucin-like domain of α DG, and acts as a bifunctional glycosyltransferase, with both xylosyltransferase and glucuronyltransferase activities, which produces repeating units of [-3-xylose- α 1,3-glucuronic acid- β 1-] (Inamori et al., 2012). Without this modification, α DG would no longer be capable of interacting with either the ECM or the arenaviral GP (Kunz et al., 2005; Rojek et al., 2007b).

While α DG has long been known to be the receptor for OW arenaviruses, recent studies have shown that additional receptor(s) may also be used by these viruses. While laminin was capable of blocking the binding of LASV GP to α DG, it could not block LASV GP mediated infection of Vero cells, indicating that the virus was able to use alternative receptor(s) (Kunz et al., 2005). In addition, mice lacking the LARGE gene were shown to be susceptible to LCMV infection at similar levels to wildtype mice, again implicating usage of alternative receptor(s) (Imperiali et al., 2008). Recently, four cellular factors have been identified to be important for LASV cellular entry. Axl, Tyro3, DC-SIGN, and LSECtin were shown to be capable of functioning as receptors independently of α DG, although LASV entry via any of these proteins is less efficient

(Shimojima et al., 2012). These receptors may be used in cell types such as hepatocytes, which show high levels of viral titers, even though DG expression is undetectable in these cells (Bedossa et al., 2002; Walker et al., 1982; Yamamoto et al., 2004). Ebola virus also uses these four receptors (Alvarez et al., 2002; Brindley et al., 2011; Gramberg et al., 2005) and shares a similar cellular tropism as LASV, targeting dendritic cells, macrophages, endothelial cells, and the liver.

While OW arenaviruses largely utilize α DG as the cellular receptor, Clade B New World arenaviruses exploit Transferrin Receptor 1 (Tfr1) as the means by which they gain entry into host cells (Radoshitzky et al., 2007). Tfr1 is responsible for the endocytosis of iron-bound transferrin, which is then transported to an acidified vesicle within the cell. Subsequently, iron is released and is then transported across the membrane into the cytoplasm (Andrews et al., 1999). The New World arenaviruses that are responsible for causing hemorrhagic fever in humans (MACV, JUNV, GTOV, SABV, and CHPV) all utilize human Transferrin Receptor 1 (hTfr1) for cellular entry (Flanagan et al., 2008). The non-pathogenic viruses Amapari (AMPV) and Tacaribe (TCRV) use Tfr1 orthologs, but are unable to gain cellular entry via hTfr1 (Abraham et al., 2009).

2.3. Membrane fusion and entry

Upon binding to the cellular receptor arenaviruses are internalized by vesicles, and are then released into the cytoplasm through

a pH-dependent membrane fusion step that is accomplished by the transmembrane portion of the viral glycoprotein, GP2 (Eschli et al., 2006). In a process unique to arenavirus entry, the Old World arenaviruses LCMV and LASV were found to subvert classical routes of endosomal trafficking. Instead of passing through the early endosomes, the viruses are delivered directly to the late endosomes. In bypassing the early compartments, these viruses have been proposed to evade detection by the host endosomal immune receptors, and therefore fail to initiate a robust innate immune signaling (Pasqual et al., 2011).

2.4. Genome replication and transcription

Arenaviral replication takes place in the cytoplasm. Due to the ambisense coding strategy of these viruses, the NP and L genes are transcribed directly from the viral genomic segments, but the GPC and Z mRNAs must be transcribed from the antigenomic strand (Fig. 3) (Günther and Lenz, 2004). The minimal trans-acting requirements for arenavirus replication and transcription are the NP and L proteins (Lee et al., 2000). Arenavirus NP encapsidates the genome, and the L polymerase performs genome replication and viral mRNA transcription. The arenaviral polymerase is an extremely large protein (~250 kDa) which, based on sequence analysis, contains four conserved domains. The RNA dependent RNA polymerase (RdRP) activity is found in domain III, and can be identified as such based on its similarity to other viral RdRPs (Vieth et al., 2004). Additionally, mutational analysis has identified two residues within the putative palm–thumb domain of the RdRP that when mutated results in a reduction in mRNA transcriptional activity without affecting antigenome replication (Hass et al., 2008). While domains II and IV are unique, resembling no other protein structures, domain I is located in the N terminus and contains endonuclease activity (Brunotte et al., 2011; Morin et al., 2010).

Arenaviruses employ a cap-snatching mechanism to obtain cellular mRNA caps to serve as primers for mRNA synthesis (Raju et al., 1990). This mechanism is also used by influenza virus, for

which the mechanism is well defined (Plotch et al., 1981). The endonuclease domain found in the N terminus of arenavirus L is proposed to cleave mRNA caps from cellular transcripts for this purpose. This domain for LCMV has been crystallized, and the structure resembles the endonuclease domain found in the N terminus of influenza PA, which is also responsible for cleaving cellular caps for this purpose (Morin et al., 2010). While the viral mRNA transcripts are capped, they are not polyadenylated (Raju et al., 1990). The arenaviral polymerase is known to oligomerize, and this multimerization may be a requirement for transcription. Subunit analysis of the polymerase has shown that the polymerase is capable of interacting via head-to-head, tail-to-tail, and head-to-tail conformations (Brunotte et al., 2011). In addition to oligomerizing, the TCRV polymerase has been shown to bind the Z matrix protein as well (Jácamo et al., 2003). Also, the L polymerases of MOPV, LASV, and LCMV have been shown to physically interact with the NP protein (Kerber et al., 2011).

The TCRV Z protein has been shown to bind both the endonuclease and the RdRP domains of the L polymerase (Jácamo et al., 2003; Wilda et al., 2008). Arenavirus Z has an inhibitory effect on viral genome replication (Cornu and de la Torre, 2001; López et al., 2001), and the interaction between TCRV Z and the polymerase appears to be essential for this transcriptional repression activity (Wilda et al., 2008). Z has been shown to lock the polymerase on the viral promoter in a catalytically inactive state, thus limiting viral replication (Kranzusch and Whelan, 2011).

2.5. Post-translational protein processing

During translation into the lumen of the ER, the SSP (stable signal peptide) of the GPC precursor protein is cleaved in this compartment by signal peptidase (Eichler et al., 2003b; York and Nunberg, 2007). The SSP remains associated with GPC, which oligomerizes into trimers in the ER before undergoing proteolytic processing by the cellular protease subtilisin kexin isozyme-1 (SKI-1)/site 1 protease (S1P) into GP1 (globular head) and GP2 (transmembrane domain) (Beyer et al., 2003; Eichler et al., 2003a). This cleavage process takes place either in the ER or the Golgi (Beyer et al., 2003; Burri et al., 2012; Lenz et al., 2001; Wright et al., 1990). The GP1 domain of the viral glycoprotein is heavily N-glycosylated, and this glycosylation is important for GP expression, cleavage, and fusion (Bonhomme et al., 2011; Eichler et al., 2006). The SSP has been shown to be important for efficient glycoprotein expression, cleavage, trafficking, formation of infectious particles, as well as membrane fusion (Messina et al., 2012; Saunders et al., 2007). The SSP has also been shown to interact with the Z protein (Capul et al., 2007). The viral Z matrix protein is required for virion budding (Perez et al., 2003; Strecker et al., 2003). The myristoylation of the G2 residue of the arenavirus Z protein has been shown to be necessary for Z self assembly and budding. This indicates that Z self association most likely occurs at the plasma membrane, where myristoylation would mediate membrane association (Loureiro et al., 2011).

2.6. Role of the Z protein in arenaviral replication

The Z protein has been shown to interact with all of the other viral proteins: NP, L, as well as GP (Capul et al., 2007; Casabona et al., 2009; Groseth et al., 2010; Levingston Macleod et al., 2011; Loureiro et al., 2011; Ortiz-Riaño et al., 2011; Shtanko et al., 2010). Recently, a review article detailing known arenaviral protein–protein interactions has been published (Loureiro et al., 2012). The interaction with the viral ribonucleoprotein (vRNP) complex likely is responsible for genome packaging into virions, and Z has been suggested to play an important role in ensuring that the L polymerase is incorporated into virion particles (Kranzusch




Fig. 3. Ambisense arenaviral genome replication strategy and protein expressions. Due to the ambisense coding strategy of the arenaviruses, the NP and L genes are transcribed directly from the viral genomic segments, but the GPC and Z mRNAs must be transcribed from the antigenomic strand after genome replication. The mRNAs are capped at the 5' ends via a cap-snatching mechanism, but are not polyadenylated at the 3' ends. The minimal trans-acting requirements for arenavirus replication and transcription are the NP and L proteins. During translation into the lumen of the ER, the viral glycoprotein (GPC) precursor is cleaved into the SSP (stable signal peptide), which remains associated with the transmembrane (GP2) subunit. The GP1 (globular head) subunit recognizes the cellular receptor and mediates cellular entry. (While only the S segment is depicted here, the L segment utilizes the same coding strategy.)

and Whelan, 2011). The intergenic region (IGR) has been shown to be important for the incorporation of LCMV genomes into virion particles (Pinschewer et al., 2005). Reports on the involvement of NP in budding activity differ among arenaviruses. One study shows the necessary involvement of ALIX/AIP1 for recruitment of NP into virion particles for MOPV. In this case, both the MOPV NP and Z proteins were found to bind cellular AIP1 (Shtanko et al., 2011). Meanwhile, the Z and NP proteins have been shown to have a direct interaction for LCMV and LASV (Ortiz-Riaño et al., 2011). The NP protein of TCRV has been shown to be required for efficient Z mediated budding activity (Groseth et al., 2010), however, the similar observation was not detected for JUNV NP. The differences between budding mechanisms for different arenaviruses offer excellent opportunities for further studies. The Z protein also undergoes homo-oligomerization, which is likely important for its function in virion budding (Kentsis et al., 2002). The fact that such a small protein can play so many roles in viral replication highlights the importance of multifunctionality in the individual viral proteins in the *Arenaviridae* family of viruses.

3. The role of individual arenaviral proteins in HF pathogenesis

3.1. Role of the glycoprotein (GP) in pathogenesis

Viral entry is the first step for viral infection, and therefore is an important factor to consider in viral pathogenesis. Viral glycoproteins display different affinities for their cellular receptor, and increased affinity may contribute to disease pathogenesis. LCMV Clone 13 (Cl 13) strain, which causes a chronic infection, has a high affinity for α DG and is able to out-compete laminin for binding to the cellular receptor, while LCMV Armstrong (ARM) strain, which causes an acute and self-limiting infection in immunocompetent mice, is unable to displace laminin. Impressively, only a single residue at position 260 of the glycoprotein (GP) is responsible for the high binding affinity of Cl 13, and is essential for viral persistence (Sullivan et al., 2011). The ability, or lack thereof, to displace laminin would therefore appear to determine tissue tropism and therefore the course of the disease for LCMV (Kunz et al., 2001; Smelt et al., 2001).

Interestingly, OW arenavirus infection has been shown to result in the downregulation of α DG while expression of the precursor DG is unaffected. This downregulation is mediated by the viral GP, which targets the interaction between DG and LARGE in the Golgi, disrupting the glycosylation of α DG. This may play an important role in viral release, and may also further contribute to the destabilization of the membrane (Rojek et al., 2007a,b). Recently, analysis of over 3 million human polymorphisms identified by the International HapMap Project revealed positive selection in a Nigerian population for allele variants of two genes, LARGE and dystrophin, a cytosolic adaptor protein that is required for the function of α DG. In this population, 21% of individuals show exposure to LASV, which may apply selective pressure on the allele frequencies in this region. These polymorphisms in LARGE and dystrophin may hinder binding and entry of LASV, affording an advantage to the immune system, and thereby protecting these individuals from severe LASV infection (Andersen et al., 2012; Sabeti et al., 2007).

Interestingly, a combination of four specific amino acid changes in hTfR1 allow entry by AMPV, while only one change is required to permit entry by TCRV. While these mutations are located in the receptor, they imply that only small changes in the viral GP would be necessary to potentially convert a non-pathogenic arenavirus into a human pathogen (Abraham et al., 2009).

While all the pathogenic NW arenaviruses are members of clade B, phylogenetic relatedness is not a good indicator of pathogenic-

ity, as nonpathogenic members are also found in this clade. Additionally, the GP of the highly pathogenic MACV is more closely related to nonpathogenic TCRV than any of the pathogenic viruses. Similarly, GTOV GP is more closely related to AMPV GP (Briese et al., 2009; Choe et al., 2011). While the relatedness of these viral glycoproteins does not provide insight into the potential for disease, the usage of hTfR1 appears to be an important factor in determination of NW arenavirus hemorrhagic fever, as all clade B viruses that utilize hTfR1 cause hemorrhagic fever in humans (Abraham et al., 2009). Whitewater Arroyo virus (WWAV), a clade A/B virus, has been loosely associated with several cases of human disease in 1999–2000, but subsequent studies do not support the notion of this arenavirus being a human pathogen. Additionally, this virus is unable to use hTfR1 as an entry receptor, and instead follows the *in vitro* tropism of nonpathogenic arenaviruses (Abraham et al., 2009; Reignier et al., 2008). This seems to suggest that this virus is not, in fact, a human pathogen.

Further evidence of the involvement in arenavirus GP as a determinant of pathogenicity can be seen in the guinea pig model of Pichinde virus (PICV) infection. While sharing high sequence identity, two strains of PICV result in vastly different disease outcomes in infected guinea pigs (Aronson et al., 1994; Jahrling et al., 1981). Mutational analysis of these two strains of Pichinde, one virulent (P18) and the other avirulent (P2), has revealed that sequence differences between the GP of these two strains of PICV contribute to the vastly different disease phenotypes. While PICV GP is not wholly responsible for the virulence difference between P2 and P18, a single mutation at position 140 of GP is able to increase the survival rate of infected animals from 0% to 33% (Kumar et al., 2012). Similarly, mutational analysis of the attenuated Candid #1 strain of JUNV has revealed that residue 427 in the G2 domain of GPC is largely responsible for the attenuation of this vaccine strain (Albariño et al., 2011b). Further analysis demonstrated that the residue change at this site results in increased fusion at neutral pH of the Candid #1 strain, and also increased dependence on hTfR1 for entry, contributing to attenuation (Droniou-Bonzom et al., 2011).

3.2. Role of the nucleoprotein (NP) in pathogenesis

Arenaviral proteins have been shown to interfere with the host's innate immune response. The NP proteins of several arenaviruses have been shown to be capable of inhibiting type I IFN signaling in reporter assays. OW LCMV and LASV along with NW JUNV, MACV, WWAV, PICV, and Latino virus (LATV) NPs were able to inhibit IFN β production through inhibition of IRF3 translocation. In contrast, apathogenic TCRV NP was incapable of IFN inhibition and of IRF3 translocation (Martínez-Sobrido et al., 2007), although these observations need to be confirmed by other laboratories. NP has been proposed to bind RIG-I, but separate studies have shown conflicting results (Pythoud et al., 2012; Zhou et al., 2010), and therefore this interaction also requires further investigation. Recently, arenavirus NP has been linked to inhibition of NF κ B signaling and IKK ϵ binding (Pythoud et al., 2012; Rodrigo et al., 2012). We and other researchers have recently crystallized LASV NP and found that its C terminus contains a functional 3'-5' exoribonuclease domain that degrades dsRNA (Hastie et al., 2011; Qi et al., 2010). This exonuclease function is directly involved in the IFN inhibition function as mutations of the catalytic residues significantly reduce its ability to inhibit IFN β production in virally infected cells (Hastie et al., 2011; Qi et al., 2010). The degradation of RNA by NP has been proposed to inhibit type I IFN by eliminating viral pattern-associated molecular pattern (PAMP) molecules that would otherwise be recognized by cellular pattern recognition receptors (PRRs). NP proteins with changes in residues that have been identified to be involved in RNA degradation function show

loss of ability to suppress IFN β production (Hastie et al., 2011; Qi et al., 2010). Interestingly, these are the same residues identified in binding IKK ϵ , suggesting that there may be some overlap in the domains responsible for these varying mechanisms of IFN inhibition, or alternatively, this could be the result of an allosteric effect (Pythoud et al., 2012). The details of how IFN inhibition by arenavirus NP is accomplished remain to be resolved, but we can safely say that this protein is a potent inhibitor of type I IFN production, and therefore it provides an excellent new target for antiviral development.

3.3. Role of the polymerase (L) protein in pathogenesis

One consistent predictor of disease outcome in LASV infected patients is viral load. Those individuals who are able to progressively control the level of viremia are able to recover, while patients who demonstrate uncontrollable viral titers in the blood typically succumb to the disease (Johnson et al., 1987). Analysis of a reverse genetics system for LASV has shown a relationship between viral replication and virulence, as well as identifying a role for both the 5' and 3' noncoding regions of the S segment in both of these aspects of viral biology (Albariño et al., 2011a). Reverse genetic techniques have also revealed that a single amino acid in the L polymerase of LCMV is responsible for the change from an acute to chronic infection between the ARM and CI 13 strains (Bergthaler et al., 2010). This residue, L1079 of CI 13, enhances the levels of intracellular viral replication, thereby increasing viral load, which accounts for the difference in rates of viral replication between the ARM and CI 13 strains. The L1079 residue was shown to be responsible for generalized immune suppression as well, which is likely a result of T cell exhaustion due to the high viral loads. A single L1079 mutation was able to confer increased replication rate, increased intracellular viral RNA levels, as well as suppression of immune responses. The addition of the GPC mutation at residue 260 was able to enhance these phenotypes in the presence of the L1079 mutation, but had no effect in the absence of the L1079 mutation. It is clear that the enhanced replicative capacity of CI 13 is the primary determinant for chronicity in LCMV infection (Bergthaler et al., 2010). Previous studies have shown that this same residue is also responsible for enhanced viral replication and tropism in macrophages (Matloubian et al., 1993). This residue does not map to any of the known catalytic domains of the polymerase, and its exact contribution to increased replication is yet to be determined (Bergthaler et al., 2010). Likewise, mutational analysis has revealed that the C terminal end of the PICV viral L polymerase might contribute to the virulence nature of the infection *in vivo* (our unpublished data).

3.4. Role of the Z protein in pathogenesis

Although it is a small protein, arenaviral Z has many binding partners, both viral and cellular. In addition to interacting with the other arenaviral proteins as discussed previously, the Z protein is known to interact with cellular promyelocytic leukemia protein (PML), which under normal conditions localizes to the nucleus. This transcription factor regulates the tumor suppressor p53 (Salomoni et al., 2012). Upon arenaviral infection, however, this cellular protein is redistributed to the cytoplasm, and has been shown to inhibit cellular apoptosis. Additionally, the interaction of Z with cellular PML has been shown to inhibit translation through interaction with the eukaryotic translation initiation factor eIF4E by reducing the binding affinity of eIF4E for cellular mRNA cap structures (Kentsis et al., 2001; Volpon et al., 2010).

The Z protein of the NW arenaviruses have been shown to inhibit type I IFN inhibition. While the Z proteins of OW LCMV and LASV showed no effect, those from NW arenaviruses could inhibit

IFN β production, albeit the effect does not appear to be as potent as that of arenaviral NP. Furthermore, NW arenavirus Z was shown to bind RIG-I, and blocked complex formation between RIG-I and MAVS, providing a mechanism for the observed IFN inhibition by the Z protein (Fan et al., 2010).

4. Antiviral compounds targeting different steps of the arenaviral life cycle

As the mechanic of the arenaviral life cycle is better understood, several compounds have been tested experimentally and in the field (i.e., ribavirin) to block different steps of the virus life cycle (Fig. 2), including entry, replication, and egress. A brief yet comprehensive review of some of these antiviral compounds is summarized below.

4.1. Compounds targeting viral entry

Many of the antivirals that are currently being developed for treatment of arenaviral HF prevent viral entry, thus preventing the establishment of infection. Amphipathic DNA polymers have been found to effectively inhibit the interaction between the glycoprotein of LCMV and α DG, thereby preventing viral entry. This interaction is independent of the sequence of the DNA polymer, but is related to its size and amphipathic nature (Lee et al., 2008a). Through the use of high throughput screening, small molecules have been identified that are able to specifically block arenavirus entry by preventing pH mediated fusion of the glycoprotein (Lee et al., 2008b). The small molecule ST-193, which is effective at blocking LASV, JUNV, MACV, and GTOV GP mediated entry, effectively blocks membrane fusion most likely through stabilization of the prefusion complex (York et al., 2008). This molecule has also been tested in the guinea pig model of LASV, and was found to significantly reduce mortality in infected animals (Cashman et al., 2011). Similarly, ST-294 is also able to stabilize the prefusion complex by targeting the interaction with G2 and the SSP, and has been shown to be effective in blocking membrane fusion with GTOV, JUNV, TCRV, and MACV GPs (York et al., 2008).

4.2. Compounds targeting the viral RNA polymerase

Broad-spectrum inhibitors of RNA viruses (ribavirin and Favipiravir or T-705) have been used for the treatment of arenavirus infections in humans and/or experimental animals (Furuta et al., 2009; Mendenhall et al., 2011b). The mechanism of action for T-705 appears to directly inhibit the viral polymerase (Furuta et al., 2009; Mendenhall et al., 2011a). Meanwhile, ribavirin (a nucleoside analog 1- β -D-ribofuranosyl-1,2,4-triazole-3-carboxamide) has been shown to be mutagenic for several RNA viruses including LCMV, indicating that lethal mutagenesis may be the mechanism by which ribavirin combats RNA virus infections (Moreno et al., 2011). Currently, the only treatment available for LASV infected patients is ribavirin. However, ribavirin is only effective if given early during the course of infection, and this treatment can lead to severe side effects (Günther and Lenz, 2004). Therefore, the discovery of new antiviral drugs for the treatment of arenaviral hemorrhagic fever is of utmost importance. Recently, peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) have been shown to efficiently block arenavirus replication. These molecules are single stranded nucleic acid analogs designed to base pair with their target sequences and effectively block gene expression. PPMOs targeting the conserved 5' end of the arenavirus genome were found to reduce virus titers not only in tissue culture but also in LCMV infected mice (Neuman et al., 2011). Another compound, designated 3f, has also been found to block JUNV RNA synthesis,

although its exact mechanism of action remains to be elucidated (Sepúlveda et al., 2012).

The endonuclease domain located in the N terminus of the L polymerase may also serve as another attractive target for drug development. This domain shares structural similarity with the endonuclease domains of orthomyxoviruses and bunyaviruses. Drugs are currently being developed against these viruses which target the endonuclease and cap snatching function in the polymerase, and these same drugs may have an application for arenaviruses as well, based on the structural and functional similarities (Ferron et al., 2012).

4.3. Compounds targeting post-translational protein modification

The cellular protease subtilisin kexin isozyme-1 (SKI-1)/site-1 protease (S1P) is involved in the proteolytic processing of the arenaviral envelope glycoprotein precursor (GPC), a step strictly required for production of infectious particles. Recent studies have suggested that SKI-1/S1P-adapted serine protease inhibitors (Maise et al., 2009) and peptide-based small molecule suicide inhibitors of SKI-1/S1P (Rojek et al., 2010) can efficiently inhibit productive arenavirus infection *in vitro* but appear to have severe limitations as antiviral drugs *in vivo*. A novel specific SKI-1/S1P inhibitor, the amino-pyrrolidine amide compound PF-429242, has recently been shown to efficiently block the biosynthesis of fusion-active mature GPC of the OW arenaviruses LCMV and LASV and has shown potent antiviral activity against LCMV and LASV in acute infection in cell culture (Urata et al., 2011). PF-429242 has recently been shown to also inhibit GPC processing and productive infection of New World arenaviruses (Pasquato et al., 2012), making PF-429242 a potential broadly active anti-arenaviral drug.

4.4. Compounds targeting the Z protein

Small molecules are being developed for use against arenaviral infection that target the viral Z protein. One such approach is through the use of siRNA against Z. The siRNAs were shown to be highly effective in reducing JUNV titer in cell culture (Artuso et al., 2009). Myristoylation of the N terminus of Z is essential for its role in budding at the cell membrane (Strecker et al., 2006). As such, myristic acid analogs have been shown to be efficacious against JUNV infection in cell culture, as well as in disrupting LASV Z protein subcellular localization (Cordo et al., 1999; Strecker et al., 2006). Other compounds target the zinc finger motif present in the Z protein structure. Several aromatic and thiuram disulfide compounds, which are known to interact with zinc finger motifs, have been shown to be effective against arenavirus infection *in vitro*, and most likely exert their effects through interaction with the Z protein (Sepúlveda et al., 2010). Another aromatic disulfide compound, NSC20625, has been shown to induce unfolding and oligomerization of Z (García et al., 2006). Additionally, this compound has been shown to disrupt the interaction of Z with cellular PML, thereby restoring formation of nuclear bodies which is normally disrupted by arenavirus Z (García et al., 2010).

5. Host immune suppression and inflammatory responses

In order to mount an effective immune response to viral infection, the pathogen must first be detected by antigen presenting cells (APCs). Dendritic cells and macrophages assume this responsibility, and once the virus has been detected by the PRRs found on these cells, they recruit other immune cells and initiate the adaptive response. One of the marked characteristics of pathogenic arenaviral infection is a generalized immune suppression of the infected hosts. Macrophages and DCs are early targets of arenavi-

rus infection. However, instead of signaling to other immune mediators, these cells fail to become activated (Baize et al., 2004) as evidenced by no increase in the production of inflammatory cytokines such as TNF α , IL-1 β , IL-6, or IL-12 in response to LASV infection. These APCs also fail to show an increase in expression of costimulatory molecules CD80 and CD86, as well as CD40, CD54, and HLAs. The phagocytic activity of the DCs is unchanged upon infection, indicating that they fail to mature in response to LASV infection. This study also shows that DCs appear to be a more important target for arenavirus infection, as infected DCs produce larger amounts of virus than infected macrophages (Baize et al., 2004).

Similar results are seen in LCMV CI 13 infected cells. While the parental LCMV ARM strain causes an acute infection in mice, the CI 13 strain results in a chronic infection, which is immunosuppressive (Althage et al., 1992). Many of the immunomodulatory effects noted in LASV infection *in vitro* are mirrored in LCMV CI 13 infection. MHCI and MHCII as well as costimulatory molecules are downregulated, therefore preventing the APCs from presenting viral antigen (Sevilla et al., 2004). Hence, they are unable to activate virus specific B cells and T cells. The lack of T cell and B cell responses is not due to malfunction in these cells, per se, but to the lack of activation from DCs, as the lymphocytes are functionally capable (Althage et al., 1992). Additionally, as seen with LASV infected cells, DCs are unable to mature and they do not undergo the changes necessary to migrate to the lymph nodes, where antigen presentation would normally occur.

While inhibition of antigen presentation by APCs is an effective method of immune suppression, LCMV CI 13 employs other mechanisms as well. As a result of CI 13 infection, DCs are stimulated to produce IL-10, an immunosuppressive cytokine, which can render T cells unresponsive. Neutralization of IL-10 results in an acute infection and clearance of the virus, rather than the chronicity that is characteristic of LCMV CI 13 infection (Brooks et al., 2006). Other evidence of immunosuppression during chronic infection with LCMV CI 13 includes T cell exhaustion and upregulation of PD-1 (programmed cell death 1). During persistent exposure to antigen, PD-1 is able to attenuate T cell receptor (TCR) signaling, and therefore inhibit T cell activation. This molecule is not upregulated in acute LCMV ARM infection. Impressively, PD-1 blockade is able to restore function to exhausted T cells, allowing infected mice to clear the virus (Barber et al., 2006). Recently, LAG-3, another inhibitory receptor, was found to be upregulated on T cells during LCMV CI 13 infection. Combined blockade of PD-1 and LAG-3 resulted in more efficient rescue of function in exhausted T cells, as well as improved control of viral load (Blackburn et al., 2009). These characteristics are not seen in acute infection with LCMV ARM.

Mopeia virus (MOPV) is another arenavirus which is closely related to LASV, but is not pathogenic in humans. In fact, MOPV has been shown to be protective against a lethal challenge with LASV infection in nonhuman primates (Fisher-Hoch et al., 2000). Therefore, analysis of the interaction of MOPV with immune cells as compared to LASV cellular interaction can give important insight into the mechanisms of LASV pathogenesis. Like LASV, the primary targets of MOPV infection are DCs and macrophages. Similarly, DCs are not activated in response to MOPV infection as evidenced by the lack of upregulation of CD80, CD86, CD54, CD40, and HLA-abc. Also, transcription of IFN α , IFN β , TNF, and IL-6 mRNA transcripts is not increased. Unlike LASV infection, macrophages did become activated in response to MOPV infection, as demonstrated by an increase in the aforementioned molecules (Pannetier et al., 2004).

This strong induction of macrophages may be an important factor for the lack of pathogenicity observed for MOPV infection as compared to LASV infection. However, in a DC and T cell coculture model, MOPV-infected DCs did become activated, most probably

through cross talk with T cells. In this model, MOPV-infected DCs were found to induce early and strong T cell responses, where LASV-infected DCs did not. These cells were able to differentiate into effector and memory T cell phenotypes in the case of MOPV infection, where LASV infection did not result in induction of effector cells, although a small number of memory cells were detected. This is likely a result of the differential responses of APCs to these two infection models (Pannetier et al., 2011). Once again, these results underscore the importance of a lack of APC activation in arenaviral pathogenesis.

While fatal LASV infection is associated with immune suppression, Argentine AHF caused by JUNV is associated with increased levels of both inflammatory and anti-inflammatory cytokines. Patients with AHF display elevated levels of IFN α , TNF α , IL-6, and IL-10 (Heller et al., 1992; Levis et al., 1985; Marta et al., 1999). Severe disease and mortality are strongly associated with elevated levels of IFN α and TNF α (Heller et al., 1992; Levis et al., 1985). However, like LASV infection, JUNV infection of macrophages does not increase cytokine production. JUNV-infected monocytes and macrophages show no increase in levels of IFN α , IFN β , TNF α , IL-10, IL-12, and IL-6. Meanwhile, apathogenic TCRV infection results in increased amounts of IL-6, IL-10, and TNF α . Therefore, macrophages do not appear to contribute to the cytokine dysregulation observed in AHF. The contribution of DCs is yet to be determined.

As suggested for LASV infection, cytokine production could play an important role in controlling JUNV replication early during the course of infection, while delayed release could contribute to pathogenesis in the case of AHF (Groseth et al., 2011). Recently, pathogenic Romero JUNV was found to induce type I IFN production in A549 cells, although the level of induction was lower than the robust response induced by the attenuated Candid #1 vaccine strain. The ability of the pathogenic virus to inhibit the type I IFN response may be cell type specific, and may suggest an alternative source of the high levels of IFN α observed in AHF patients in the absence of any appreciable induction in APCs as seen in tissue culture (Huang et al., 2012). Understanding the mechanisms of immune suppression and inflammation in response to arenaviral hemorrhagic fever infection will provide new opportunities for the development of therapeutic agents to modify the host response against these deadly human pathogens to limit the host disease process.

6. Conclusion

Although arenaviruses have a very limited number of gene products, these proteins play multiple roles in contributing to the pathogenesis of arenavirus HF. The glycoprotein plays an essential role in cellular tropism, and the binding affinity for the cellular receptor has also proven to be an important determinant for viral pathogenicity. Also, the ability of OW arenaviruses to subvert classical routes of endosomal trafficking may allow these viruses to go undetected by endosomal receptors. Viral replicative capacity is a major pathogenic determinant for arenavirus infection, and the L polymerase plays a critical role in this process. Mutations in the polymerase affect the rate of viral replication, hence attenuating the disease pathogenesis. When interacting with cellular PML, the viral Z matrix protein can inhibit apoptosis as well as interfere with protein translation. In addition, the Z protein of NW arenaviruses can interact with components of the innate signaling pathway, and is able to inhibit type I IFN production albeit not to the levels observed with the viral NP protein. The effect of NP protein in inhibiting IFN β production has been associated with the exoribonuclease function located in the C-terminal domain of the protein. This domain has also been implicated in binding to IKK ϵ , thereby possibly inhibiting multiple signaling steps required for IFN β production. Development of antivirals targeting various steps

of the viral life cycle may allow for a multipronged approach for combating arenavirus infection, and provide an approach that will not only halt arenaviruses in the very beginning stages of infection but also help patients who suffer from more advanced disease.

Acknowledgements

This work was supported by NIH Grants AI083409 to Y.L. and R01AI093580 and R56AI091805 to H.L. We apologize to colleagues whose work might not have been cited in this article due to space constraint.

References

- Abraham, J., Kwong, J.A., Albariño, C.G., Lu, J.G., Radoshitzky, S.R., Salazar-Bravo, J., Farzan, M., Spiropoulou, C.F., Choe, H., 2009. Host-species transferrin receptor 1 orthologs are cellular receptors for nonpathogenic New World Clade B arenaviruses. *PLoS Pathog.* 5, e1000358.
- Aguilar, P.V., Camargo, W., Vargas, J., Guevara, C., Roca, Y., Felices, V., Laguna-Torres, V.A., Tesh, R., Ksiazek, T.G., Kochel, T.J., 2009. Reemergence of Bolivian hemorrhagic fever, 2007–2008. *Emerging Infect. Dis.* 15, 1526–1528.
- Al-Zein, N., Boyce, T.G., Correa, A.G., Rodriguez, V., 2008. Meningitis caused by lymphocytic choriomeningitis virus in a patient with leukemia. *J. Pediatr. Hematol. Oncol.* 30, 781–784. <http://dx.doi.org/10.1097/MPH.0b013e318182e72b>.
- Albariño, C.G., Bird, B.H., Chakrabarti, A.K., Dodd, K.A., Erickson, B.R., Nichol, S.T., 2011a. Efficient rescue of recombinant Lassa virus reveals the influence of 5' segment noncoding regions on virus replication and virulence. *J. Virol.* 85, 4020–4024.
- Albariño, C.G., Bird, B.H., Chakrabarti, A.K., Dodd, K.A., Flint, M., Bergeron, É., White, D.M., Nichol, S.T., 2011b. The major determinant of attenuation in mice of the Candid1 vaccine for Argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain. *J. Virol.* 85, 10404–10408.
- Althage, A., Odermatt, B., Moskopidhis, D., Kündig, T., Hengartner, U.H.-R.H., Zinkernagel, R.M., 1992. Immunosuppression by lymphocytic choriomeningitis virus infection: competent effector T and B cells but impaired antigen presentation. *Eur. J. Immunol.* 22, 1803–1812.
- Alvarez, C.P., Lasala, F., Carrillo, J., Muñiz, O., Corbí, A.L., Delgado, R., 2002. C-Type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. *J. Virol.* 76, 6841–6844.
- Ambrosio, A., Saavedra, M., Mariani, M., Gamboa, G., Maiza, A., 2011. Argentine hemorrhagic fever vaccines. *Hum. Vaccin.* 7, 694–700.
- Andersen, K.G., Shylakhter, I., Tabrizi, S., Grossman, S.R., Hapji, C.T., Sabeti, P.C., 2012. Genome-wide scans provide evidence for positive selection of genes implicated in Lassa fever. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 367, 868–877.
- Andrews, N.C., Fleming, M.D., Levy, J.E., 1999. Molecular insights into mechanisms of iron transport. *Curr. Opin. Hematol.* 6, 61.
- Aronson, J., Herzog, N., Jerrells, T., 1994. Pathological and virological features of arenavirus disease in guinea pigs. Comparison of two Pichinde virus strains. *Am. J. Pathol.* 145, 228–235.
- Artuso, M.C., Ellenberg, P.C., Scolaro, L.A., Damonte, E.B., García, C.C., 2009. Inhibition of Junin virus replication by small interfering RNAs. *Antiviral Res.* 84, 31–37.
- Baize, S., Kaplon, J., Faure, C., Pannetier, D., Georges-Courbot, M.-C., Deubel, V., 2004. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. *J. Immunol.* 172, 2861–2869.
- Barber, D.L., Wherry, E.J., Masopust, D., Zhu, B., Allison, J.P., Sharpe, A.H., Freeman, G.J., Ahmed, R., 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature* 439, 682–687.
- Bedossa, P., Ferlicot, S., Paradis, V., Dargere, D., Bonvoust, F., Vidaud, M., 2002. Dystroglycan expression in hepatic stellate cells: role in liver fibrosis. *Lab. Invest.* 82, 1053–1061.
- Bergthaler, A., Flatz, L., Hegazy, A.N., Johnson, S., Horvath, E., Löhning, M., Pinschewer, D.D., 2010. Viral replicative capacity is the primary determinant of lymphocytic choriomeningitis virus persistence and immunosuppression. *Proc. Natl. Acad. Sci.* 107, 21641–21646.
- Beyer, W.R., Pöplau, D., Garten, W., von Laer, D., Lenz, O., 2003. Endoproteolytic processing of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P. *J. Virol.* 77, 2866–2872.
- Blackburn, S.D., Shin, H., Haining, W.N., Zou, T., Workman, C.J., Polley, A., Betts, M.R., Freeman, G.J., Vignali, D.A.A., Wherry, E.J., 2009. Coregulation of CD8⁺ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. *Nat. Immunol.* 10, 29–37.
- Bonhomme, C.J., Capul, A.A., Lauron, E.J., Bederka, L.H., Knopp, K.A., Buchmeier, M.J., 2011. Glycosylation modulates arenavirus glycoprotein expression and function. *Virology* 409, 223–233.
- Bonthuis, D.J., 2012. Lymphocytic choriomeningitis virus: an underrecognized cause of neurologic disease in the fetus, child, and adult. *Semin. Pediatr. Neurol.* 19, 89–95.
- Briese, T., Paweska, J.T., McMullan, L.K., Hutchison, S.K., Street, C., Palacios, G., Khristova, M.L., Weyer, J., Swanepoel, R., Egholm, M., Nichol, S.T., Lipkin, W.I.,

2009. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from Southern Africa. *PLoS Pathog.* 5, e1000455.
- Brindley, M.A., Hunt, C.L., Kondratowicz, A.S., Bowman, J., Sinn, P.L., McCray Jr., P.B., Quinn, K., Weller, M.L., Chiorini, J.A., Maury, W., 2011. Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein. *Virology* 415, 83–94.
- Brooks, D.G., Trifilo, M.J., Edelmann, K.H., Teyton, L., McGavern, D.B., Oldstone, M.B.A., 2006. Interleukin-10 determines viral clearance or persistence in vivo. *Nat. Med.* 12, 1301–1309.
- Brunotte, L., Lelke, M., Hass, M., Kleinstueber, K., Becker-Ziaja, B., Günther, S., 2011. Domain structure of Lassa virus L protein. *J. Virol.* 85, 324–333.
- Burri, D.J., Pasqual, G., Rochat, C., Seidah, N.G., Pasquato, A., Kunz, S., 2012. Molecular characterization of the processing of arenavirus envelope glycoprotein precursors by subtilisin kexin Isozyme-1/site-1 protease. *J. Virol.* 86, 4935–4946.
- Cao, W., Henry, M., Borrow, P., Yamada, H., Elder, J., Ravkov, E., Nichol, S., Compans, R., Campbell, K., Oldstone, M., 1998. Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. *Science* 282, 2079–2081.
- Capul, A.A., Perez, M., Burke, E., Kunz, S., Buchmeier, M.J., de la Torre, J.C., 2007. Arenavirus Z-glycoprotein association requires Z myristoylation but not functional ring or late domains. *J. Virol.* 81, 9451–9460.
- Casabona, J.C., Levingston Macleod, J.M., Loureiro, M.E., Gomez, G.A., Lopez, N., 2009. The RING domain and the L79 residue of Z protein are involved in both the rescue of nucleocapsids and the incorporation of glycoproteins into infectious chimeric arenavirus-like particles. *J. Virol.* 83, 7029–7039.
- Cashman, K.A., Smith, M.A., Twenhafel, N.A., Larson, R.A., Jones, K.F., Allen Iii, R.D., Dai, D., Chinsangaram, J., Bolken, T.C., Hruby, D.E., Amberg, S.M., Hensley, L.E., Guttieri, M.C., 2011. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. *Antiviral Res.* 90, 70–79.
- Centers for Disease Control and Prevention, 2008. Brief report: lymphocytic choriomeningitis virus transmitted through solid organ transplantation – Massachusetts, 2008. *Morb. Mortal. Wkly. Rep.* 57, 799–801.
- Charrel, R.N., Lamballerie, X.d., 2003. Arenaviruses other than Lassa virus. *Antiviral Res.* 57, 89–100.
- Choe, H., Jemielny, S., Abraham, J., Radoshitzky, S.R., Farzan, M., 2011. Transferrin receptor 1 in the zoonosis and pathogenesis of New World hemorrhagic fever arenaviruses. *Curr. Opin. Microbiol.* 14, 476–482.
- Cordo, S.M., Candurra, N.A., Damonte, E.B., 1999. Myristic acid analogs are inhibitors of Junin virus replication. *Microbes Infect.* 1, 609–614.
- Cornu, T.I., de la Torre, J.C., 2001. RING finger Z protein of Lymphocytic Choriomeningitis Virus (LCMV) inhibits transcription and RNA replication of an LCMV S-segment minigenome. *J. Virol.* 75, 9415–9426.
- Cummins, D., McCormick, J.B., Bennett, D., et al., 1990. Acute sensorineural deafness in Lassa fever. *JAMA* 264, 2093–2096.
- Delgado, S., Erickson, B.R., Agudo, R., Blair, P.J., Vallejo, E., Albariño, C.G., Vargas, J., Comer, J.A., Rollin, P.E., Ksiazek, T.G., Olson, J.G., Nichol, S.T., 2008. Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. *PLoS Pathog.* 4, e1000047.
- Droniou-Bonzom, M.E., Reignier, T., Oldenburg, J.E., Cox, A.U., Exline, C.M., Rathbun, J.Y., Cannon, P.M., 2011. Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP. *J. Virol.* 85, 13457–13462.
- Eichler, R., Lenz, O., Garten, W., Strecker, T., 2006. The role of single N-glycans in proteolytic processing and cell surface transport of the Lassa virus glycoprotein GP-C. *J. Virol.* 80, 3, 41.
- Eichler, R., Lenz, O., Strecker, T., Eickmann, M., Klenk, H.-D., Garten, W., 2003a. Identification of Lassa virus glycoprotein signal peptide as a trans-acting maturation factor. *EMBO Rep.* 4, 1084–1088.
- Eichler, R., Lenz, O., Strecker, T., Garten, W., 2003b. Signal peptide of Lassa virus glycoprotein GP-C exhibits an unusual length. *FEBS Lett.* 538, 203–206.
- Enria, D.A., Briggiler, A.M., Sánchez, Z., 2008. Treatment of Argentine hemorrhagic fever. *Antiviral Res.* 78, 132–139.
- Eschli, B., Quirin, K., Wepf, A., Weber, J., Zinkernagel, R., Hengartner, H., 2006. Identification of an N-terminal trimeric coiled-coil core within arenavirus glycoprotein 2 permits assignment to class I viral fusion proteins. *J. Virol.* 80, 5897–5907.
- Fan, L., Briese, T., Lipkin, W.I., 2010. Z proteins of New World arenaviruses bind RIG-I and interfere with Type I interferon induction. *J. Virol.* 84, 1785–1791.
- Ferron, F., Decroly, E., Selisko, B., Canard, B., 2012. The viral RNA capping machinery as a target for antiviral drugs. *Antiviral Res.* 96, 21–31.
- Fischer, S.A., Graham, M.B., Kuehnert, M.J., Kotton, C.N., Srinivasan, A., Marty, F.M., Comer, J.A., Guarnier, J., Paddock, C.D., DeMeo, D.L., Shieh, W.-J., Erickson, B.R., Bandy, U., DeMaria, A., Davis, J.P., Delmonico, F.L., Pavlin, B., Likos, A., Vincent, M.J., Sealy, T.K., Goldsmith, C.S., Jernigan, D.B., Rollin, P.E., Packard, M.M., Patel, M., Rowland, C., Helfand, R.F., Nichol, S.T., Fishman, J.A., Ksiazek, T., Zaki, S.R., 2006. Transmission of lymphocytic choriomeningitis virus by organ transplantation. *N. Engl. J. Med.* 354, 2235–2249.
- Fisher-Hoch, S.P., Hutwagner, L., Brown, B., McCormick, J.B., 2000. Effective vaccine for Lassa fever. *J. Virol.* 74, 6777–6783.
- Flanagan, M.L., Oldenburg, J., Reignier, T., Holt, N., Hamilton, G.A., Martin, V.K., Cannon, P.M., 2008. New World Clade B arenaviruses can use Transferrin Receptor 1 (TfR1)-dependent and -independent entry pathways, and glycoproteins from human pathogenic strains are associated with the use of TfR1. *J. Virol.* 82, 938–948.
- Fulhorst, C.F., Cajimat, M.N.B., Milazzo, M.L., Paredes, H., de Manzione, N.M.C., Salas, R.A., Rollin, P.E., Ksiazek, T.G., 2008. Genetic diversity between and within the arenavirus species indigenous to western Venezuela. *Virology* 378, 205–213.
- Furuta, Y., Takahashi, K., Shiraki, K., Sakamoto, K., Smeed, D.F., Barnard, D.L., Gowen, B.B., Julander, J.G., Morrey, J.D., 2009. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. *Antiviral Res.* 82, 95–102.
- García, C.C., Djavani, M., Topisirovic, I., Borden, K.L.B., Salvato, M.S., Damonte, E.B., 2006. Arenavirus Z protein as an antiviral target: virus inactivation and protein oligomerization by zinc finger-reactive compounds. *J. Gen. Virol.* 87, 1217–1228.
- García, C.C., Topisirovic, I., Djavani, M., Borden, K.L.B., Damonte, E.B., Salvato, M.S., 2010. An antiviral disulfide compound blocks interaction between arenavirus Z protein and cellular promyelocytic leukemia protein. *Biochem. Biophys. Res. Commun.* 393, 625–630.
- Gramberg, T., Hofmann, H., Möller, P., Lator, P.F., Marzi, A., Geier, M., Krumbiegel, M., Winkler, T., Kirchhoff, F., Adams, D.H., Becker, S., Münch, J., Pöhlmann, S., 2005. LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus. *Virology* 340, 224–236.
- Groseth, A., Hoenen, T., Weber, M., Wolff, S., Herwig, A., Kaufmann, A., Becker, S., 2011. Tacaribe virus but not junin virus infection induces cytokine release from primary human monocytes and macrophages. *PLoS Negl. Trop. Dis.* 5, e1137.
- Groseth, A., Wolff, S., Strecker, T., Hoenen, T., Becker, S., 2010. Efficient budding of the Tacaribe virus matrix protein Z requires the nucleoprotein. *J. Virol.* 84, 3603–3611.
- Günther, S., Lenz, O., 2004. Lassa virus. *Crit. Rev. Clin. Lab. Sci.* 41, 339–390.
- Harrison, L.H., Halsey, N.A., McKee, K.T., Peters, C.J., Barrera Oro, J.G., Briggiler, A.M., Feuillade, M.R., Maiztegui, J.I., 1999. Clinical case definitions for Argentine hemorrhagic fever. *Clin. Infect. Dis.* 28, 1091–1094.
- Hass, M., Lelke, M., Busch, C., Becker-Ziaja, B., Günther, S., 2008. Mutational evidence for a structural model of the Lassa virus RNA polymerase domain and identification of two residues, Gly1394 and Asp1395, that are critical for transcription but not replication of the genome. *J. Virol.* 82, 10207–10217.
- Hastie, K.M., Kimberlin, C.R., Zandonatti, M.A., MacRae, I.J., Saphire, E.O., 2011. Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease activity essential for immune suppression. *Proc. Natl. Acad. Sci.* 108, 2396–2401.
- Heller, M.V., Saavedra, M.C., Falcoff, R., Maiztegui, J.I., Molinas, F.C., 1992. Increased tumor necrosis factor- α levels in Argentine hemorrhagic fever. *J. Infect. Dis.* 166, 1203–1204.
- Huang, C., Kolokoltsova, O.A., Yun, N.E., Seregin, A.V., Poussard, A.L., Walker, A.G., Brasier, A.R., Zhao, Y., Tian, B., de la Torre, J.C., Paessler, S., 2012. Junin virus infection activates the Type I interferon pathway in a RIG-I-dependent manner. *PLoS Negl. Trop. Dis.* 6, e1659.
- Imperiali, M., Spörri, R., Hewitt, J., Oxenius, A., 2008. Post-translational modification of α -dystroglycan is not critical for lymphocytic choriomeningitis virus receptor function in vivo. *J. Gen. Virol.* 89, 2713–2722.
- Inamori, K.-I., Yoshida-Moriguchi, T., Hara, Y., Anderson, M.E., Yu, L., Campbell, K.P., 2012. Dystroglycan function requires xylosyl- and glucuronyltransferase activities of LARGE. *Science* 335, 93–96.
- Jácomo, R., López, N., Wilda, M., Franze-Fernández, M.T., 2003. Tacaribe virus Z protein interacts with the L polymerase protein to inhibit viral RNA synthesis. *J. Virol.* 77, 10383–10393.
- Jahring, P.B., Hesse, R.A., Rhoderick, J.B., Elwell, M.A., Moe, J.B., 1981. Pathogenesis of a Pichinde virus strain adapted to produce lethal infections in guinea pigs. *Infect. Immun.* 32, 872–880.
- Johnson, K.M., McCormick, J.B., Webb, P.A., Smith, E.S., Elliott, L.H., King, I.J., 1987. Clinical virology of Lassa fever in hospitalized patients. *J. Infect. Dis.* 155, 456–464.
- Kentsis, A., Dwyer, E.C., Perez, J.M., Sharma, M., Chen, A., Pan, Z.Q., Borden, K.L.B., 2001. The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E. *J. Mol. Biol.* 312, 609–623.
- Kentsis, A., Gordon, R.E., Borden, K.L.B., 2002. Self-assembly properties of a model RING domain. *Proc. Natl. Acad. Sci.* 99, 667–672.
- Kerber, R., Rieger, T., Busch, C., Flatz, L., Pinschewer, D.D., Kümmerer, B.M., Günther, S., 2011. Cross-species analysis of the replication complex of old world arenaviruses reveals two nucleoprotein sites involved in L protein function. *J. Virol.* 85, 12518–12528.
- Kranzusch, P.J., Whelan, S.P.J., 2011. Arenavirus Z protein controls viral RNA synthesis by locking a polymerase–promoter complex. *Proc. Natl. Acad. Sci.* 108, 19743–19748.
- Kumar, N., Wang, J., Lan, S., Danzy, S., McLay, S., Schelde, L., Seladi-Schulman, J., Ly, H., Liang, Y., 2012. Characterization of virulence-associated determinants in the envelope glycoprotein of Pichinde virus. *Virology* 433, 97–103.
- Kunz, S., Rojek, J.M., Kanagawa, M., Spiropoulou, C.F., Barresi, R., Campbell, K.P., Oldstone, M.B.A., 2005. Posttranslational modification of α -dystroglycan, the cellular receptor for arenaviruses, by the glycosyltransferase LARGE is critical for virus binding. *J. Virol.* 79, 14282–14296.
- Kunz, S., Sevilla, N., McGavern, D.B., Campbell, K.P., Oldstone, M.B.A., 2001. Molecular analysis of the interaction of LCMV with its cellular receptor α -dystroglycan. *J. Cell Biol.* 155, 301–310.
- Lee, A.M., Rojek, J.M., Gundersen, A., Ströher, U., Juteau, J.-M., Vaillant, A., Kunz, S., 2008a. Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers. *Virology* 372, 107–117.

- Lee, A.M., Rojek, J.M., Spiropoulou, C.F., Gundersen, A.T., Jin, W., Shaginan, A., York, J., Nunberg, J.H., Boger, D.L., Oldstone, M.B.A., Kunz, S., 2008b. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. *J. Biol. Chem.* 283, 18734–18742.
- Lee, K.J., Novella, I.S., Teng, M.N., Oldstone, M.B.A., de la Torre, J.C., 2000. NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. *J. Virol.* 74, 3470–3477.
- Lenz, O., ter Meulen, J., Klenk, H.-D., Seidah, N.G., Garten, W., 2001. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. *Proc. Natl. Acad. Sci.* 98, 12701–12705.
- Levingston Macleod, J.M., D'Antuono, A., Loureiro, M.E., Casabona, J.C., Gomez, G.A., Lopez, N., 2011. Identification of two functional domains within the arenavirus nucleoprotein. *J. Virol.* 85, 2012–2023.
- Levis, S.C., Saavedra, M.C., Ceccoli, C., Feuillade, M.R., Enria, D.A., Maiztegui, J.I., Falcoff, R., 1985. Correlation between endogenous interferon and the clinical evolution of patients with Argentine hemorrhagic fever. *J. Interferon Res.* 5, 383–389.
- Lisieux, T., Coimbra, M., Nassar, E.S., Burattini, M.N., Souza, L.T.M.d., Ferreira, I.B., Rocco, I.M., Rosa, A.P.A.T.d., Vasconcelos, P.F.C., Pinheiro, F.P., LeDuc, J.W., Rico-Hesse, R., Gonzalez, J.-P., Jahrling, P.B., Tesh, R.B., 1994. New arenavirus isolated in Brazil. *Lancet* 343, 391–392.
- López, N., Jácamo, R., Franze-Fernández, M.a.T., 2001. Transcription and RNA replication of Tacaribe virus genome and antigenome analogs require N and L proteins: Z protein is an inhibitor of these processes. *J. Virol.* 75, 12241–12251.
- Loureiro, M.E., D'Antuono, A., Levingston Macleod, J.M., López, N., 2012. Uncovering viral protein–protein interactions and their role in arenavirus life cycle. *Viruses* 4, 1651–1667.
- Loureiro, M.E., Wilda, M., Levingston Macleod, J.M., D'Antuono, A., Foscaldi, S., Buslje, C.M., Lopez, N., 2011. Molecular determinants of arenavirus Z protein homo-oligomerization and L polymerase binding. *J. Virol.* 85, 12304–12314.
- MacNeil, A., Stroher, U., Farnon, E., Campbell, S., Cannon, D., Paddock, C.D., Drew, C.P., Kuehnert, M., Knust, B., Gruenfelder, R., Zaki, S.R., Rollin, P.E., Nichol, S.T., team, L.T.I., 2012. Solid organ transplant-associated lymphocytic choriomeningitis, United States, 2011. *Emerging Infect. Dis.* 18, 1256–1262.
- Maisa, A., Ströher, U., Klenk, H.-D., Garten, W., Strecker, T., 2009. Inhibition of Lassa virus glycoprotein cleavage and multicycle replication by Site 1 protease-adapted α_1 -antitrypsin variants. *PLoS Negl. Trop. Dis.* 3, e446.
- Maiztegui, J.I., McKee, K.T., Oro, J.G.B., Harrison, L.H., Gibbs, P.H., Feuillade, M.R., Enria, D.A., Briggiler, A.M., Levis, S.C., Ambrosio, A.M., Halsey, N.A., Peters, C.J.AHF Study Group, 1998. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. *J. Infect. Dis.* 177, 277–283.
- Manziona, N.d., Salas, R.A., Paredes, H., Godoy, O., Rojas, L., Araoz, F., Fulhorst, C.F., Ksiazek, T.G., Mills, J.N., Ellis, B.A., Peters, C.J., Tesh, R.B., 1998. Venezuelan hemorrhagic fever: clinical and epidemiological studies of 165 cases. *Clin. Infect. Dis.* 26, 308–313.
- Marta, R.F., Montero, V.S., Hack, C.E., Sturk, A., Maiztegui, J.I., Molinas, F.C., 1999. Proinflammatory cytokines and elastase- α_1 -antitrypsin in Argentine hemorrhagic fever. *Am. J. Trop. Med. Hyg.* 60, 85–89.
- Martínez-Sobrido, L., Giannakas, P., Cubitt, B., García-Sastre, A., de la Torre, J.C., 2007. Differential inhibition of Type I interferon induction by arenavirus nucleoproteins. *J. Virol.* 81, 12696–12703.
- Matloubian, M., Kolhekar, S.R., Somasundaram, T., Ahmed, R., 1993. Molecular determinants of macrophage tropism and viral persistence: importance of single amino acid changes in the polymerase and glycoprotein of lymphocytic choriomeningitis virus. *J. Virol.* 67, 7340–7349.
- McCormick, J.B., 1999. Lassa fever. In: Saluzzo, J.F., Dodet, B. (Eds.), *Emergence and Control of Rodent-borne Viral Diseases*. Elsevier, pp. 177–195.
- Mendenhall, M., Russell, A., Juelich, T., Messina, E.L., Smee, D.F., Freiberg, A.N., Holbrook, M.R., Furuta, Y., Torre, J.d.l., Nunberg, J.H., Gowen, B., 2011a. T-705 (Favipiravir) inhibition of arenavirus replication in cell culture. *Antimicrob. Agents Chemother.* 55, 782–787.
- Mendenhall, M., Russell, A., Smee, D.F., Hall, J.O., Skirpstunas, R., Furuta, Y., Gowen, B.B., 2011b. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever. *PLoS Negl. Trop. Dis.* 5, e1342.
- Messina, E.L., York, J., Nunberg, J.H., 2012. Dissection of the role of the stable signal peptide of the arenavirus envelope glycoprotein in membrane fusion. *J. Virol.* 86, 6138–6145.
- Moraz, M.-L., Kunz, S., 2010. Pathogenesis of arenavirus hemorrhagic fevers. *Expert Rev. Anti Infect. Ther.* 9, 49–59.
- Moreno, H., Gallego, I., Sevilla, N., de la Torre, J.C., Domingo, E., Martín, V., 2011. Ribavirin can be mutagenic for arenaviruses. *J. Virol.* 85, 7246–7255.
- Morin, B., Coutard, B., Lelke, M., Ferron, F., Kerber, R., Jamal, S., Frangeul, A., Baronti, C., Charrel, R., de Lamballerie, X., Vornrhein, C., Lescar, J., Bricogne, G., Günther, S., Canard, B., 2010. The N-terminal domain of the arenavirus L protein is an rna endonuclease essential in mRNA transcription. *PLoS Pathog.* 6, e1001038.
- Neuman, B., Bederka, L., Stein, D., Ting, J., Moulton, H., Buchmeier, M., 2011. Development of peptide-conjugated morpholino oligomers as pan-arenavirus inhibitors. *Antimicrob. Agents Chemother.* 55, 4631–4638.
- Ortiz-Riaño, E., Cheng, B.Y.H., de la Torre, J.C., Martínez-Sobrido, L., 2011. The C-terminal region of lymphocytic choriomeningitis virus nucleoprotein contains distinct and segregable functional domains involved in NP-Z interaction and counteraction of the Type I interferon response. *J. Virol.* 85, 13038–13048.
- Pannetier, D., Faure, C., Georges-Courbot, M.-C., Deubel, V., Baize, S., 2004. Human macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in response to mopeia virus infection. *J. Virol.* 78, 10516–10524.
- Pannetier, D., Reynard, S., Russier, M., Journeaux, A., Tordo, N., Deubel, V., Baize, S., 2011. Human dendritic cells infected with the nonpathogenic mopeia virus induce stronger T-cell responses than those infected with Lassa virus. *J. Virol.* 85, 8293–8306.
- Pasqual, G., Rojek, J.M., Masin, M., Chatton, J.-Y., Kunz, S., 2011. Old World arenaviruses enter the host cell via the multivesicular body and depend on the endosomal sorting complex required for transport. *PLoS Pathog.* 7, e1002232.
- Pasquato, A., Rochat, C., Burri, D.J., Pasqual, G., la Torre, J.C.d., Kunz, S., 2012. Evaluation of the anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1 protease inhibitor PF-429242. *Virology* 423, 14–22.
- Paweska, J.T., Sewall, N.H., Ksiazek, T.G., Blumberg, L.H., Hale, M.J., Lipkin, W.I., Weyer, J., Nichol, S.T., Rollin, P.E., McMullan, L.K., Paddock, C.D., Briese, T., Mnyalaza, J., Dinh, T.-H., Mukonka, V., Ching, P., Duse, A., Richards, G., Jong, G.M., Cohen, C., Ikalafeng, B., Mugeru, C., Asomugha, C., Malotle, M.M., Nteo, D.M., Misiani, E., Swanepoel, R., Zaki, S.R. Outbreak Control and Investigation Teams, 2009. Nosocomial outbreak of novel arenavirus infection, southern Africa. *Emerging Infect. Dis.* 15, 1598–1602.
- Perez, M., Craven, R.C., de la Torre, J.C., 2003. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. *Proc. Natl. Acad. Sci.* 100, 12978–12983.
- Perez, M., de la Torre, J.C., 2003. Characterization of the genomic promoter of the prototypic arenavirus lymphocytic choriomeningitis virus. *J. Virol.* 77, 1184–1194.
- Peters, C.J., 2006. Lymphocytic choriomeningitis virus – an old enemy up to new tricks. *N. Engl. J. Med.* 354, 2208–2211.
- Pfau, C.J., 1996. Arenaviruses. In: Baron, S. (Ed.), *Medical Microbiology*. The University of Texas Medical Branch at Galveston, Galveston, TX.
- Pinschewer, D.D., Perez, M., de la Torre, J.C., 2005. Dual role of the lymphocytic choriomeningitis virus intergenic region in transcription termination and virus propagation. *J. Virol.* 79, 4519–4526.
- Plotch, S.J., Bouloy, M., Ulmanen, I., Krug, R.M., 1981. A unique cap(m7G pppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. *Cell* 23, 847–858.
- Pythoud, C., Rodrigo, W.W.S.I., Pasqual, G., Rothenberger, S., Martínez-Sobrido, L., de la Torre, J.C., Kunz, S., 2012. Arenavirus nucleoprotein targets interferon regulatory factor-activating kinase IKK ϵ . *J. Virol.* 86, 7728–7738.
- Qi, X., Lan, S., Wang, W., Schelde, L.M., Dong, H., Wallat, G.D., Ly, H., Liang, Y., Dong, C., 2010. Cap binding and immune evasion revealed by Lassa nucleoprotein structure. *Nature* 468, 779–783.
- Radoshitzky, S.R., Abraham, J., Spiropoulou, C.F., Kuhn, J.H., Nguyen, D., Li, W., Nagel, J., Schmidt, P.J., Nunberg, J.H., Andrews, N.C., Farzan, M., Choe, H., 2007. Transferrin receptor 1 is a cellular receptor for New World hemorrhagic fever arenaviruses. *Nature* 446, 92–96.
- Raju, R., Raju, L., Hacker, D., Garcin, D., Compans, R., Kolakofsky, D., 1990. Nontemplated bases at the 5' ends of Tacaribe virus mRNAs. *Virology* 74, 53–59.
- Reignier, T., Oldenburg, J., Flanagan, M.L., Hamilton, G.A., Martin, V.K., Cannon, P.M., 2008. Receptor use by the Whitewater Arroyo virus glycoprotein. *Virology* 371, 439–446.
- Rodrigo, W.W.S.I., Ortiz-Riaño, E., Pythoud, C., Kunz, S., de la Torre, J.C., Martínez-Sobrido, L., 2012. Arenavirus nucleoproteins prevent activation of nuclear factor kappa B. *J. Virol.* 86, 8185–8197.
- Rojek, J.M., Campbell, K.P., Oldstone, M.B.A., Kunz, S., 2007a. Old World arenavirus infection interferes with the expression of functional α -dystroglycan in the host cell. *Mol. Biol. Cell* 18, 4493–4507.
- Rojek, J.M., Moraz, M.-L., Pythoud, C., Rothenberger, S., Van der Goot, F.G., Campbell, K.P., Kunz, S., 2012. Binding of Lassa virus perturbs extracellular matrix-induced signal transduction via dystroglycan. *Cell. Microbiol.* 14, 1122–1134.
- Rojek, J.M., Pasqual, G., Sanchez, A.B., Nguyen, N.-T., de la Torre, J.-C., Kunz, S., 2010. Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses. *J. Virol.* 84, 573–584.
- Rojek, J.M., Spiropoulou, C.F., Campbell, K.P., Kunz, S., 2007b. Old World and Clade C New World arenaviruses mimic the molecular mechanism of receptor recognition used by α -dystroglycan's host-derived ligands. *J. Virol.* 81, 5685–5695.
- Rousseau, M.C., Saron, M.F., Brouqui, P., Bourgeade, A., 1997. Lymphocytic choriomeningitis virus in southern France. Four case reports and a review of the literature. *Eur. J. Epidemiol.* 13, 817–823.
- Sabeti, P.C., Varilly, P., Fry, B., Lohmueller, J., Hostetter, E., Cotsapas, C., Xie, X., Byrne, E.H., McCarroll, S.A., Gaudet, R., Schaffner, S.F., Lander, E.S., 2007. Genome-wide detection and characterization of positive selection in human populations. *Nature* 449, 913–918.
- Salomoni, P., Dvorkina, M., Michod, D., 2012. Role of the promyelocytic leukaemia protein in cell death regulation. *Cell Death Dis.* 3, e247.
- Saunders, A.A., Ting, J.P.C., Meisner, J., Neuman, B.W., Perez, M., de la Torre, J.C., Buchmeier, M.J., 2007. Mapping the landscape of the lymphocytic choriomeningitis virus stable signal peptide reveals novel functional domains. *J. Virol.* 81, 5649–5657.
- Sepúlveda, C.S., García, C.C., Damonte, E.B., 2010. Inhibition of arenavirus infection by thiuram and aromatic disulfides. *Antiviral Res.* 87, 329–337.
- Sepúlveda, C.S., García, C.C., Fascio, M.L., D'Accorso, N.B., Docampo Palacios, M.L., Pellón, R.F., Damonte, E.B., 2012. Inhibition of Junin virus RNA synthesis by an antiviral acridone derivative. *Antiviral Res.* 93, 16–22.

- Sevilla, N., Kunz, S., Holz, A., Lewicki, H., Homann, D., Yamada, H., Campbell, K.P., de la Torre, J.C., Oldstone, M.B.A., 2000. Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. *J. Exp. Med.* 192, 1249–1260.
- Sevilla, N., McGavern, D.B., Teng, C., Kunz, S., Oldstone, M.B.A., 2004. Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion. *J. Clin. Invest.* 113, 737–745.
- Shimojima, M., Ströher, U., Ebihara, H., Feldmann, H., Kawaoka, Y., 2012. Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry. *J. Virol.* 86, 2067–2078.
- Shtanko, O., Imai, M., Goto, H., Lukashevich, I.S., Neumann, G., Watanabe, T., Kawaoka, Y., 2010. A role for the C terminus of Mopeia virus nucleoprotein in its incorporation into Z protein-induced virus-like particles. *J. Virol.* 84, 5415–5422.
- Shtanko, O., Watanabe, S., Jasenosky, L.D., Watanabe, T., Kawaoka, Y., 2011. ALIX/AIP1 is required for NP incorporation into Mopeia virus Z-induced virus-like particles. *J. Virol.* 85, 3631–3641.
- Smelt, S.C., Borrow, P., Kunz, S., Cao, W., Tishon, A., Lewicki, H., Campbell, K.P., Oldstone, M.B.A., 2001. Differences in affinity of binding of lymphocytic choriomeningitis virus strains to the cellular receptor α -dystroglycan correlate with viral tropism and disease kinetics. *J. Virol.* 75, 448–457.
- Spiropoulou, C.F., Kunz, S., Rollin, P.E., Campbell, K.P., Oldstone, M.B.A., 2002. New World arenavirus Clade C, but not Clade A and B viruses, utilizes α -dystroglycan as its major receptor. *J. Virol.* 76, 5140–5146.
- Strecker, T., Eichler, R., Meulen, J.t., Weissenhorn, W., Dieter Klenk, H., Garten, W., Lenz, O., 2003. Lassa virus Z protein is a matrix protein sufficient for the release of virus-like particles. *J. Virol.* 77, 10700–10705.
- Strecker, T., Maisa, A., Daffis, S., Eichler, R., Lenz, O., Garten, W., 2006. The role of myristoylation in the membrane association of the Lassa virus matrix protein Z. *J. Virol.* 80, 93.
- Sullivan, B.M., Emonet, S.F., Welch, M.J., Lee, A.M., Campbell, K.P., de la Torre, J.C., Oldstone, M.B.A., 2011. Point mutation in the glycoprotein of lymphocytic choriomeningitis virus is necessary for receptor binding, dendritic cell infection, and long-term persistence. *Proc. Natl. Acad. Sci.* 108, 2969–2974.
- Urata, S., Yun, N., Pasquato, A., Paessler, S., Kunz, S., de la Torre, J.C., 2011. Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. *J. Virol.* 85, 795–803.
- Vieth, S., Torda, A.E., Asper, M., Schmitz, H., Günther, S., 2004. Sequence analysis of L RNA of Lassa virus. *Virology* 318, 153–168.
- Volpon, L., Osborne, M.J., Capul, A.A., de la Torre, J.C., Borden, K.L.B., 2010. Structural characterization of the Z RING-eIF4E complex reveals a distinct mode of control for eIF4E. *Proc. Natl. Acad. Sci.* 107, 5441–5446.
- Walker, D., McCormick, J., Johnson, K., Webb, P., Komaba-Kono, G., Elliott, L., Gardner, J., 1982. Pathologic and virologic study of fatal Lassa fever in man. *Am. J. Pathol.* 107, 349–356.
- Wilda, M., Lopez, N., Casabona, J.C., Franze-Fernandez, M.T., 2008. Mapping of the Tacaribe arenavirus Z-protein binding sites on the L protein identified both amino acids within the putative polymerase domain and a region at the N terminus of L that are critically involved in binding. *J. Virol.* 82, 11454–11460.
- Wright, K.E., Spiro, R.C., Burns, J.W., Buchmeier, M.J., 1990. Post-translational processing of the glycoproteins of lymphocytic choriomeningitis virus. *Virology* 177, 175–183.
- Wright, R., Johnson, D., Neumann, M., Ksiazek, T.G., Rollin, P., Keech, R.V., Bonthius, D.J., Hitchon, P., Grose, C.F., Bell, W.E., Bale, J.F., 1997. Congenital lymphocytic choriomeningitis virus syndrome: a disease that mimics congenital toxoplasmosis or cytomegalovirus infection. *Pediatrics* 100, e9.
- Yamamoto, T., Kato, Y., Karita, M., Kawaguchi, M., Shibata, N., Kobayashi, M., 2004. Expression of genes related to muscular dystrophy with lissencephaly. *Pediatr. Neurol.* 31, 183–190.
- York, J., Dai, D., Amberg, S.M., Nunberg, J.H., 2008. PH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors. *J. Virol.* 82, 10932–10939.
- York, J., Nunberg, J.H., 2007. Distinct requirements for signal peptidase processing and function in the stable signal peptide subunit of the Junin virus envelope glycoprotein. *Virology* 359, 72–81.
- Zhou, S., Cerny, A.M., Zacharia, A., Fitzgerald, K.A., Kurt-Jones, E.A., Finberg, R.W., 2010. Induction and inhibition of Type I interferon responses by distinct components of lymphocytic choriomeningitis virus. *J. Virol.* 84, 9452–9462.